Reported Sunday, Taiho And Cullinan's REZILIENT3 Trial Meets Primary Endpoint, Zipalertinib Combination Shows PFS Hazard Ratio Of 0.50 Versus Chemotherapy Alone
Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion
A new medicine combo worked better than old treatment in a big test. When doctors watch this company, they can look for whether patients stay healthier longer.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.